home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Genetic News | search  
 

A Potential Drug Target For Diabetes

 
  June, 29 2001 23:41
your information resource in human molecular genetics
 
     
Diabetes is the world's most common metabolic disorder. By 2025, the number of adults with diabetes is expected to reach 300 million worldwide. The disease, which is associated with obesity and inactivity, is the sixth leading cause of death in the United States, killing nearly 200,000 people every year.

In diabetes, there is too much glucose in the blood. People with type I diabetes cannot produce enough insulin to trigger the conversion of food to energy. Insulin works by stimulating the uptake of glucose into cells and by suppressing the production of glucose by the liver. People with the more common type 2 diabetes produce enough insulin but the cells that normally respond to insulin fail to do so.

To develop new therapies for diabetes it is important to identify and understand how the many components of the insulin-signaling pathway work. This pathway includes protein kinases and phosphatases. Protein kinases transfer phosphate from the high-energy molecule ATP to a particular amino acid on target proteins, thus regulating the activity of these proteins. The pathway is switched off by phosphatases that remove phosphate from proteins. Protein kinases and phosphatases are both potential targets for therapeutic intervention.

One possible drug target is the protein kinase GSK3beta. It is known to regulate blood glucose levels and becomes less active when cells are stimulated with insulin. Now, in the July issue of Nature Structural Biology (Vol. 8, No. 7), ter Haar and coworkers of Vertex Pharmaceuticals Inc. in Cambridge, Massachusetts, USA, have solved the three-dimensional crystal structure of the protein. The structure explains a unique property of this enzyme, namely, that it prefers to add phosphates to proteins that have already been phosphorylated. This finding may help in the design of specific inhibitors of this enzyme.

Contact:

Dr. Ernst ter Haar
Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, Massachusetts 02139-4211
USA
Telephone: 617 577 6243
Fax: 617 577 6400
Email: ernst_terhaar@vpharm.com

(C) Nature Structural Biology press release.


Message posted by: Trevor M. D'Souza

print this article mail this article
Bookmark and Share this page (what is this?)

Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.

Use the links below to share this article on the social bookmarking site of your choice.

Read more about social bookmarking at Wikipedia - Social Bookmarking

Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2016 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.